Novo Holdings has made a €86 million investment in 21st.Bio, a Danish bioindustrial scale-up company.
21st.Bio supports bioindustrial companies with matters such as the upscaling of molecular innovation or large-scale production that can meet market demands and advance the green transition globally.
One core focal area for 21st.Bio is producing proteins and peptides that can be utilised for the food, materials and agricultural industries.
21st.Bio’s technology platform originates from selected parts of Novozymes, which provides a co-exclusive license to 21st.Bio within certain boundaries of applications.
Access to selected parts of Novozymes’ R&D platform and the investment by Novo Holdings will enable the company to expand its capabilities even further.
Thomas Schmidt, co-founder and CEO of 21st.Bio, said: “Many brilliant industrial biotech ideas never succeed, because production challenges result in too high price points for the final product. Hence, a vast number of otherwise great innovations do not make it to a scale at which they are truly relevant for the world”.
He continued: “At 21st.Bio, we can help establish the right technology for producing novel molecules and peptides and hence help innovators successfully make the difficult step from innovation to big business and impact for the planet. We have gained access to a selection of Novozymes’ unique technology platform on commercial terms, which means that a success for 21st.Bio is also a success for Novozymes.”
Søren Møller, managing partner of Novo Seeds at Novo Holdings, will join the company’s board of directors.
By Lauren Ford
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.